(a) The commission or the commission’s agent shall publicly disclose, immediately after the board’s deliberations conclude, each specific drug recommended for or against preferred drug list status for each drug class included in the preferred drug list for the Medicaid vendor drug program. The disclosure must include:
(1) the general basis for the recommendation for each drug class; and
(2) for each recommendation, whether a supplemental rebate agreement or program benefit agreement was reached under Subchapter C.
(b) The disclosure must be posted on the commission’s Internet website not later than the 10th business day after the date of conclusion of board deliberations that result in recommendations made to the executive commissioner regarding the placement of drugs on the preferred drug list.

Text of section effective on April 01, 2025